{Reference Type}: Journal Article
{Title}: The Mifepristone Case and the Legitimacy of the FDA.
{Author}: Gluck AR;
{Journal}: JAMA
{Volume}: 329
{Issue}: 24
{Year}: 2023 06 27
{Factor}: 157.335
{DOI}: 10.1001/jama.2023.8712
{Abstract}: This Viewpoint discusses a recent federal court decision that invaliated the Food and Drug Administration’s (FDA) approval of mifepristone, a drug used to end pregnancies and manage miscarriage when used with misoprostol, and how that decision challenges the legitimacy and independence of the FDA.